drugset
drugset / Trial / NCT05996952

RC48-ADC in Adjuvant/Salvage Treatment of HER2 Positive Non-muscle-invasive Bladder Cancer

NCT05996952 ↗

Phase 2 Not yet recruiting 77 enrolled West China Hospital RemeGen Co., Ltd. · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the efficacy and safety of intravenous RC48-ADC in adjuvant/salvage treatment of HER2 positive high-risk non-muscle-invasive bladder cancer.

Timeline

Start
2023-08
Primary completion
2025-08
Completion
2026-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Disitamab Vedotin Monoclonal antibody 2 mg/kg Intravenous

Indications

urinary bladder carcinoma